Hematopoietic cell transplant for CML

Fiona C He, Erica D Warlick

Research output: Chapter in Book/Report/Conference proceedingChapter


Treatment for CML, and specifically the use of allogeneic hematopoietic cell transplant (HCT), has changed dramatically since the entry of tyrosine kinase inhibitors (TKIs) into clinical practice. While HCT remains the only curative therapy, the availability of numerous oral TKIs has moved transplant later in the treatment paradigm given an overall improved side effect profile and diminished morbidity. However, despite an improved side effect/risk profile, long-term follow-up with TKIs suggests that treatment dropout occurs due to resistance or intolerance and thus the role of transplant is still important. Our chapter reviews the history of HCT for CML, the current outcomes in the TKI era, and outlines a paradigm for timing of transplant.

Original languageEnglish (US)
Title of host publicationChronic Myeloid Leukemia
Subtitle of host publicationFrom Daily Management to Complicated Issues
PublisherNova Science Publishers, Inc.
Number of pages8
ISBN (Electronic)9781629489926
ISBN (Print)9781629489711
StatePublished - Jan 1 2014


Dive into the research topics of 'Hematopoietic cell transplant for CML'. Together they form a unique fingerprint.

Cite this